| Name | Title | Contact Details |
|---|
Endotronix, a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. The Cordella™ Heart Failure System includes a cloud-based disease-management system and a breakthrough implantable wireless pulmonary artery pressure sensor. The seamlessly integrated system enables proactive management and early detection of worsening heart failure, which promotes ongoing therapeutic interventions to improve quality of life, reduce hospital readmissions, and lower care costs.
EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. vBloc Therapy is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.* *Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.
Visionix is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sarstedt Group is a Newton, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GlucoTec is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.